Legislation codifies FDA’s science-based approach to biosimilar review by limiting comparative efficacy studies; Introduced and Passed House Committee This Week WASHINGTON (July 23, 2026) —
Legislative progress codifies FDA’s science-based approach to biosimilar review by limiting comparative efficacy studies; Eliminates arbitrary distinction between interchangeable biologics and biosimilars WASHINGTON (July 21,
Legislation codifies FDA’s science-based approach to biosimilar review by limiting comparative efficacy studies WASHINGTON (July 15, 2026) — The Biosimilars Council and the Association for
Biosimilar Red Tape Elimination Act and Medication Affordability and Patent Integrity Act address longstanding barriers inhibiting patient access to lower-cost prescription options WASHINGTON (June 17,
Skinny Labels are vital for U.S. patient affordability; Calls on Congress to act WASHINGTON (June 3, 2026) — The Association for Accessible Medicines commented on
Highlights commitment and rigorous holistic approach to quality medicines WASHINGTON (June 3, 2026) — The Association for Accessible Medicines today commented on a hearing held
Thanks President and Administration for recognizing importance of generics WASHINGTON (May 18, 2026) — The Association for Accessible Medicines commented on the announcement today that
Thanks the Administration for working with AAM and industry WASHINGTON (April 2, 2026) — The Association for Accessible Medicines today applauded the proclamation signed by
FDA draft guidance removes redundant PK testing requirements where scientifically rigorous data already exists WASHINGTON (March 10, 2026) — The Association for Accessible Medicines and
Outlines four key policy areas Congress can act on now to protect generic and biosimilar medicines and provide access and savings for patients WASHINGTON (February
Applauds Q1/Q2 passage; Calls for additional PBM reform WASHINGTON (February 3, 2026) — The Association for Accessible Medicines today applauded passage of Q1/Q2 legislation as
WASHINGTON (January 29, 2026) — The Board of Directors of the Association for Accessible Medicines has elected Bob Hoffman as Chair. Hoffman, Chief Commercial Officer
